

Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

A Systematic Review

Xavier Bosch, MD, PhD

Antonio Guilabert, MD

Gerard Espinosa, MD, PhD

Eduard Mirapeix, MD, PhD

SYSTEMIC VASCULITIS WITH POSITIVITY for antineutrophil cytoplasmic antibodies (ANCA) constitutes a subgroup of disorders affecting small- to medium-sized vessels and includes Wegener granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome.¹ The incidences of these life-threatening conditions vary from 2.4 cases per million for Churg-Strauss syndrome to 3.6 for microscopic polyangiitis² to 10 cases for Wegener granulomatosis.³

Among other manifestations, pauci-immune necrotizing and crescentic glomerulonephritis and pulmonary capillaritis are common features of Wegener granulomatosis and microscopic polyangiitis; however, patients with Wegener granulomatosis and Churg-Strauss syndrome exhibit granulomatous inflammation of the respiratory tract, which is rich in eosinophils in the latter syndrome. Furthermore, patients with Churg-Strauss syndrome present with asthma and peripheral eosinophilia and the heart may be involved, mostly as rapid-onset heart failure. However, vasculitic damage is usually less severe than in micro-

Context Immunosuppressive therapies for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis have greatly advanced patient survival but have turned ANCA-associated vasculitis (AAV) into chronic, relapsing disorders. Long-term treatment and disease-related morbidity are major threats. The last decade has seen a collaborative international effort to determine effective treatment.

Objective To analyze the reported evidence on AAV therapy in order to provide physicians with a rational approach for dealing with various clinical scenarios.

Data Sources We searched English-language articles on the medical treatment of AAV published between 1966 and March 2007 using MEDLINE. Articles from the reference lists of the most relevant articles retrieved were also analyzed.

Study Selection Studies of current available drug treatments or medical interventions for patients with AAV were included. Duplicate publications, case reports, and uncontrolled trials and series including fewer than 10 patients were excluded.

Data Synthesis We included 2 meta-analyses, 20 randomized controlled prospective trials, and 62 uncontrolled trials with more than 10 patients or observational studies. Outcome measures and treatment protocols were heterogeneous across trials. Cotrimoxazole can be used alone or in combination with corticosteroids to induce and maintain remission in cases of isolated upper respiratory tract involvement. To induce remission, methotrexate plus corticosteroids can be used instead of cyclophosphamide for patients with generalized, non-organ-threatening disease. When methotrexate is used as maintenance therapy, the likelihood of relapse is high and rigorous monitoring is mandatory. Pulse cyclophosphamide with corticosteroids can be used to induce remission in patients with generalized organ-threatening disease. The combination of azathioprine and daily prednisone is effective in maintaining remission. Plasma exchange is at present the best complement to immunosuppressants in advanced renal disease. In Churg-Strauss syndrome, treatment can be started with high doses of corticosteroids, tapering them when the clinical situation improves. In patients with a high risk of death, cyclophosphamide should be introduced.

Conclusions Although AAV therapies should be tailored to the patient's specific clinical situation, evidence for treatment of several disease states is lacking. There is a need for safer and more effective drugs.

JAMA. 2007;298(6):655-669

www.jama.com

See also Patient Page.



CME available online at
www.jama.com

Author Affiliations: Departments of Internal Medicine (Dr Bosch), Dermatology (Dr Guilabert), Auto-immune Diseases (Dr Espinosa), and Nephrology (Dr Mirapeix), Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain.

Corresponding Author: Xavier Bosch, MD, PhD,

Department of Internal Medicine, Hospital Clínic, Vil-larroel 170, 08036-Barcelona, Spain (xavbosch@clinic .ub.es).

Clinical Review Section Editor: Michael S. Lauer, MD. We encourage authors to submit papers for consideration as a Clinical Review. Please contact Michael S. Lauer, MD, at michael.lauer@jama-archives.org.

scopic polyangiitis and Wegener granulomatosis.^{1,2} Compelling evidence on the pathogenic role of ANCA in vasculitis comes from in vitro and murine studies. However, the influence of ANCA in granulomatous lesions seems negligible (FIGURE 1 and FIGURE 2).

Over the last 10 years, collaborative international research efforts have sought to determine the most effective AAV therapy, including several randomized controlled trials and numerous ongoing trials, some probing exciting alternatives to nonideal im-


munosuppressants.⁴ It is accepted that studies should be designed according to different disease states to obtain therapies tailored to patients' needs.⁴ This activity is boosted by continuing discoveries in AAV pathogenesis. The objective of this article is to analyze the reported evidence on AAV therapy to provide physicians with a rational clinical approach for different scenarios.

EVIDENCE ACQUISITION

We systematically searched MEDLINE for English-language articles published

between 1966 and March 2007 for studies in humans using the terms (singly and in combination) *ANCA-associated vasculitis*, *microscopic polyarteritis*, *microscopic polyangiitis*, *necrotizing glomerulonephritis*, and *necrotizing glomerulonephritis* and the Medical Subject Heading terms *Wegener Granulomatosis*, *Churg-Strauss Syndrome* and *Antibodies, Antineutrophil Cytoplasmic*. We also manually searched the reference list of relevant articles retrieved (mostly review articles; FIGURE 3) and identified 4174 references.

Figure 1. Model of Pathogenesis of Granulomatous Inflammation in Wegener Granulomatosis and Therapeutic Immune Response Targets



Immune response therapies and targets are indicated in blue boldface text.

^aCsernok E, Ai M, Gross WL, et al. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. *Blood*. 2006;107(11):4440-4448.

^bVoswinkel J, Mueller A, Kraemer JA, et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. *Ann Rheum Dis*. 2006;65(7):859-864.

Two authors (A.G. and G.E.) read the titles and abstracts (if available) looking for articles on current available drug therapy or medical interventions for any AAV (inclusion criterion). Articles considered by both authors to meet this criterion were fully reviewed. Duplicate publications, case reports, and uncontrolled trials and series with fewer than 10 patients were excluded. Two meta-analyses, 20 randomized controlled prospective trials, and 62 uncontrolled trials with more than 10 patients or observational studies were finally analyzed.

EVIDENCE SYNTHESIS

Rationale for the Current Approach

When the natural history of Wegener granulomatosis was described in 1958,⁵ it was usually a fatal disease without effective treatment and patient survival after diagnosis averaged 5 months. The introduction in the 1960s of corticosteroids only extended average survival by 8 months.⁶ This changed radically when Fauci and Wolff⁷ pioneered the use of cyclophosphamide in the early 1970s. The administration of daily oral cyclophosphamide (1-2 mg/kg) and prednisone (1 mg/kg) resulted in a dramatic clinical benefit. Prednisone was tapered and dis-

continued within 6 to 9 months, while cyclophosphamide was maintained at least for a year once remission was achieved.

A long-term evaluation of 158 patients with Wegener granulomatosis who had undergone this schedule showed that 75% achieved complete remission with an 87% survival rate.⁸ However, 42% of patients had permanent treatment-related morbidity. Adverse events included cyclophosphamide-cystitis (43%), infertility (57% [16 of 28] fertile women analyzed), infections (0.11 infections per patient-year, including 6 episodes of *Pneumocystis jiroveci* pneumonia and 34

Figure 2. Model of Pathogenesis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Wegener Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome and Therapeutic Immune Response Targets





Figure 3. Process for Study Inclusion

episodes of herpes zoster), myelodysplasia (2%), and an overall 2.4-fold increase in risk of malignancy (bladder cancer, 33-fold increase; lymphoma, 11-fold increase).⁸ Thus, efficacious strategies to reduce the accumulated cyclophosphamide dose are urgently needed. It is now known that patients entering remission following cyclophosphamide induction therapy can be switched to less toxic azathioprine as maintenance therapy.⁹ Furthermore, patients with less severe disease can achieve remission with methotrexate with a success rate similar to that of cyclophosphamide.¹⁰

Although these schedules minimize the devastating adverse effects of cyclophosphamide, refractory cases exist (10%)¹¹ and relapses are fairly common even in treated patients. Due to repeated bouts of disease activity and long-term treatment-related morbidity, accumulative organ damage is a major threat.¹² Moreover, there is no agreement on the duration of maintenance therapy.¹³ At this point, research on pathogenic-oriented therapies may provide better answers to the AAV treatment quandary.

Data on AAV treatment stem mainly from studies of patients with Wegener granulomatosis, with a consensual description of microscopic polyangiitis being adopted in 1994.¹⁴ Due to the

overlap between Wegener granulomatosis and microscopic polyangiitis, some patients classified as having Wegener granulomatosis probably had microscopic polyangiitis.¹⁵ This, together with the similar response to therapy (and their low incidence), has meant that the 2 conditions are considered together for therapeutic investigation.

Given the shortage of randomized trials, it is not easy to propose a guideline for AAV treatment. The methods used in these studies is heterogeneous with different definitions for remission, relapse, and disease states.¹¹ Furthermore, both the initial dose of glucocorticoids and immunosuppressants and the tapering schemes vary.

The most logical strategy is to design the treatment according to the clinical situation.¹⁶ Jayne et al¹⁷ for the European Vasculitis Study (EUVAS) group defined several subgroups of patients covering the spectrum of AAV severity. To aid understanding, we have slightly modified the clinical characteristics of EUVAS subgroups to allow the inclusion of patients from other studies with similar but not identical features.

Localized Disease

The EUVAS definition refers to patients with symptoms restricted to the upper and/or lower airways, without constitutional symptoms or systemic vasculitis.

Remission Induction. In the 1980s, DeRemee and colleagues^{18,19} reported favorable responses to cotrimoxazole alone or in combination with cyclophosphamide plus corticosteroids in 11 of 12 patients with Wegener granulomatosis. Seven patients fulfilled criteria of localized Wegener granulomatosis. A positive result was also seen in a subsequent study,²⁰ with 11 of 19 patients with localized Wegener granulomatosis responding to cotrimoxazole with complete (n=6) or partial (n=5) remission lasting a median of 43 months.²⁰

Remission Maintenance. In the only randomized study of cotrimoxazole as remission maintenance in localized disease, cotrimoxazole, or placebo twice daily was initiated after remission was

achieved with cyclophosphamide plus corticosteroids.²¹ Eight patients with localized Wegener granulomatosis were included in the cotrimoxazole group and 7 received placebo. Half were treated with corticosteroids. After 24 months, relapses were less frequent in the cotrimoxazole group (18% vs 40%).²¹ Relapse rates were significantly lower in patients with upper respiratory tract disease but not in those with renal or lung involvement.

Recommendation. Owing to its favorable response rates and the favorable adverse-effect profile, cotrimoxazole, in our opinion, can be used alone or in combination with corticosteroids to induce and maintain remission when disease is limited to the upper respiratory tract (See levels of evidence for recommendations in TABLE 1).

Generalized Non–Organ-Threatening Disease (Early Systemic Disease)

EUVAS defined *early systemic disease* as patients with localized Wegener granulomatosis with constitutional symptoms or with multifocal Wegener granulomatosis or microscopic polyangiitis without threatened organ function. Serum creatinine levels must be lower than 1.7 mg/dL.¹⁷ There may be lung involvement, but the partial pressure of oxygen must be higher than 70 mm Hg and the diffusing lung capacity of carbon monoxide must be more than 70%. Other reports have used the terms *limited* or *nonlife* or *non-organ threatening* to refer to patients with normal or moderately impaired renal function with serum creatinine levels lower than 2.5 mg/dL.²³⁻²⁷ To convert from milligrams per deciliter to millimoles per liter, multiply by 88.4.

Remission Induction. Studies have analyzed the effectiveness and safety of immunosuppressants less aggressive than cyclophosphamide, with methotrexate being the most tested^{10,23-28} (TABLE 2), including 4 prospective, uncontrolled studies.²³⁻²⁶ Remission rates ranged from 35%²⁶ to 74%.²⁵ The lower rate of treatment success achieved in 1 trial²⁶ may be explained by the different

doses of concomitant corticosteroids. The EUVAS' Non-Renal Wegener's Granulomatosis Treated Alternatively With Methotrexate (NORAM) study by de Groot et al¹⁰ is the only trial to compare the effectiveness and safety of methotrexate plus corticosteroids with oral cyclophosphamide plus corticosteroids for induction of remission. Six months after initiation of therapy, the remission rate in the methotrexate group (89.8%) was not significantly lower than in the cyclophosphamide group (93.5%). Of note, remission was delayed among patients in the methotrexate group who had more extensive disease or pulmonary involvement.

Etanercept is a tumor necrosis factor α (TNF- α)–blocking fusion protein that

contains the ligand-binding domain of the human TNF- α receptor 2. The rationale for the use of TNF- α blockers in AAV stems from (1) a positive correlation between TNF- α serum levels and disease activity; (2) the presence of TNF- α in vasculitic lesions; (3) in vitro evidence for a role of TNF- α in neutrophil priming (Figure 2); (4) the efficacy of TNF- α blockade in suppressing vasculitis in an animal model³¹; and (5) the predominance of T-helper cells with a T-helper type 1 cytokine repertoire including TNF- α in Wegener granulomatosis granulomata (Figure 1).³²

The Wegener's Granulomatosis Etanercept Trial (WGET)^{27,28} assessed the efficacy of etanercept in the treatment of Wegener granulomatosis. One

hundred eight patients were randomly assigned to receive etanercept or placebo in addition to standard therapy (corticosteroids plus cyclophosphamide for patients with severe disease and corticosteroids plus methotrexate for patients with limited disease).²⁷ No differences were found in remission rates with the addition of etanercept or placebo to methotrexate and corticosteroids. Of note, 6 patients in the etanercept group, and none in the placebo group, developed solid cancers, although all patients were treated with cyclophosphamide. It is possible that the combination of TNF- α inhibitors and cyclophosphamide increases the risk of cancer beyond that observed with cyclophosphamide alone.

Table 1. Treatment for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Disease State	Remission Induction		Remission Maintenance ^a		Comments
	Treatment Recommendation	Level of Evidence/Grade of Recommendation ^b	Treatment Recommendation	Level of Evidence/Grade of Recommendation ^b	
Wegener Granulomatosis and Microscopic Polyangiitis					
Localized disease	Cotrimoxazole ± corticosteroids ^c	2b/B	Cotrimoxazole ± corticosteroids	1b/A	
Generalized non-organ-threatening disease	Methotrexate + corticosteroids	1b/A	Methotrexate + corticosteroids ^d	2b/B	When methotrexate is used for maintenance therapy, monitor closely for relapse.
Generalized organ-threatening disease	Pulse cyclophosphamide + corticosteroids	1a/A	Azathioprine + corticosteroids ^d	1b/A	For refractory disease, see Table 4. For patients who test positive for proteinase-3 ANCA at the time of switching to azathioprine, monitor closely for relapse. For patients with contraindications or intolerance to azathioprine, consider alternative therapy with leflunomide (1b/A), methotrexate (1b/A), or mycophenolate mofetil (4/C)
Severe renal vasculitis	Cyclophosphamide + corticosteroids + plasma exchange	1b/A	Azathioprine + corticosteroids ^d	5/D	For refractory disease, see Table 4.
Diffuse pulmonary hemorrhage	High-dose cyclophosphamide + pulse methylprednisolone	5/D	Azathioprine + corticosteroids ^d	5/D	For refractory disease, see Table 4.
	Cyclophosphamide + corticosteroids + plasma exchange	4/C			
Churg-Strauss Syndrome					
FFS≥1	Cyclophosphamide + corticosteroids	1a/A	Less toxic immunosuppressant		
FFS=0	Corticosteroids	1a/A	Low-dose corticosteroids if persistent asthma	4/C	

Abbreviation: FFS, 5-factors score.

^aIn cases of minor relapse (recurrence or new onset of non-organ- and non-life-threatening disease activity) consider adjusting immunosuppressants and/or corticosteroids.

^bLevel of evidence and grade of recommendation follow the Oxford Centre for Evidence-Based Medicine definitions.²²

^cAdd cotrimoxazole to prevent infection by *Pneumocystis jirovecii* when using immunosuppressants.

^dMaintain immunosuppressants and taper corticosteroids for at least 12 to 18 months.

Table 2. Studies on Methotrexate for Remission Induction and/or Maintenance in Patients With Generalized Non–Organ-Threatening Disease

	Sneller et al, ²⁴ 1995	De Groot et al, ²⁶ 1998	Stone et al, ²⁵ 1999	DeGroot et al, ¹⁰ 2005	WGET, ²⁸ 2005	Langford et al, ²⁹ 2003	Reinhold-Keller et al, ³⁰ 2002
Type of study	Prospective uncontrolled	Prospective uncontrolled	Prospective uncontrolled	Randomized controlled trial	Randomized controlled trial	Prospective uncontrolled	Prospective uncontrolled
Phase of treatment	Induction and maintenance	Induction and maintenance	Induction and maintenance	Induction and maintenance	Induction and maintenance	Maintenance	Maintenance
No. of patients	42	17	19	95	52	22	71
Disorder	Wegener granulomatosis	Wegener granulomatosis	Wegener granulomatosis	89 Wegener granulomatosis 6 Microscopic polyangiitis	Wegener granulomatosis	Wegener granulomatosis	Wegener granulomatosis
Comparison treatment				49 Methotrexate; 46 Cyclophosphamide	52 Methotrexate; 122 Cyclophosphamide		
Lung involvement, %	52	18	47	50	NS	NS	NS
Renal involvement, % ^a	50 < 2.5 mg/dL	24 < 1.7 mg/dL	47 < 1.2 mg/dL	31 = 0.95 mg/dL	NS < 1.4 mg/dL	NS < 2.5 mg/dL	NS < 1.5 mg/dL
Nervous system involvement, %	0	0	11	25	NS	NS	NS
Initial dose of methotrexate per wk	0.3 mg/kg	0.3 mg/kg ^b	7.5-10 mg	15 mg	0.25 mg/kg	0.3 mg/kg	7.5 mg ^b
Maximum dose of methotrexate per wk	20-25 mg	NS	18.7 mg	20-25 mg	25 mg	25 mg	22.5
Time of methotrexate treatment, mean ^c	14.5 mo	24.5 In responders, 14 in nonresponders	23.7 wk	12 mo	12 mo After achievement of remission	At least 24 mo	25.2 mo
Concomitant prednisone	1 mg/kg per d, tapered to alternate day dosage, then to 0	10 mg/d (5-50 mg/d)	40 mg/d (20-60 mg/d), tapered to 20 mg within 2 mo	1 mg/kg per d, tapered to 15 mg at 12 wk, and discontinued by 12 mo	0.5-1 mg/kg per d, discontinued within 6 mo	1 mg/kg per d, tapered to alternate d dosage then to 0 ^e	1 mg/kg per d, tapered to 20 mg at 4 wk and discontinued by 6 mo
Definitions of complete remission	Absence of active disease, pulmonary infiltrates, systemic inflammatory disease, and stabilization or improvement of renal features	Absence of abnormalities in clinical, radiological, and immunological data	Absence of active disease in any organ for at ≤1 mo without treatment	Absence of new or worse disease activity (BVAS 1) but allowed persistent activity (BVAS 2) in 1 item scoring <2 points ^d	Sustained remission, BVAS 0 for at least 6 mo; Remission, BVAS 0		
Complete remission, %	71	35	74	89.8 Methotrexate; 93.5 Cyclophosphamide	67.3 Methotrexate; 74.6 Cyclophosphamide ^e		
Time to remission, mean ^c	4.2	NS	NS	3 Methotrexate; 2 Cyclophosphamide	NS		
Definitions of relapse	Return of the categories of disease after remission	Reemergence of symptoms after remission	Recurrence of active Wegener granulomatosis after remission	Recurrence or new onset of vasculitis activity (clinical manifestations) after remission	Increase of at least 1 point in the BVAS ^f	Return of the categories of disease after remission	Reemergence of symptoms after complete or partial remission (at least 3 mo)
Relapses, %	37	40	57	69.5 Methotrexate; 46.5 Cyclophosphamide ^f	NS	73	37
Time to relapse, mean ^c	29	NS	10	13 Methotrexate; 15 Cyclophosphamide	NS	15	19.4
Toxic effects, %	50	12	42	38 Adverse events in 46 patients	NS	NS	NS
Liver dysfunction	10	0	6	7	NS	1	0
Infection	4	0	0	9	NS	NS	7
Leukopenia	3	0	0	4	NS	NS	9
Pneumonitis	3	0	0	0	NS	2	0
Mucositis	1	1	0	0	NS	NS	0
Gastrointestinal event	0	1	2	1	NS	NS	0

Abbreviations: BVAS, Birmingham Vasculitis Activity Score; MPA, microscopic polyangiitis; NS, not specified; WGET, Wegener's Granulomatosis Etanercept Trial.

^aMaximum serum creatinine level (to convert creatinine from mg/dL to mmol/L, multiply by 88.4).^bMethotrexate was administered by intravenous route.^cResults are expressed in months. In DeGroot et al¹⁰ and WGET,²⁸ result is referred to as median time.^dBVAS 1 scores represent new or worse disease activity, and BVAS 2 scores represent persistent low-grade disease activity.^ePercentages are referred as sustained remission.^fStatistically significant.

Remission Maintenance. Most data on the role of methotrexate in remission maintenance in generalized non–organ-threatening disease comes from nonrandomized studies (TABLE 3),^{24-26,28-30,41-43} with relapse rates varying between 37% and 73%. In general, these patients were taking only methotrexate at the time of relapse.^{29,30,41} The high number of renal relapses (66%) is noteworthy.³⁰ De Groot et al⁴² demonstrated that low-dose

methotrexate (0.3 mg/kg once weekly) was superior to cotrimoxazole for remission maintenance (91% vs 58%) in 65 patients with generalized non–organ-threatening Wegener granulomatosis, results similar to those previously reported by Reinhold-Keller et al²⁰ who showed that neither cotrimoxazole alone nor cotrimoxazole plus low-dose prednisone sustained remission in non–organ-threatening Wegener granulomatosis.

The NORAM¹⁰ trial (n=100) was devised as a remission induction and not as a remission maintenance trial. Relapse rates at 18 months were unexpectedly high (70% in the methotrexate group and 47% in the cyclophosphamide group), with 45% of the methotrexate group and 30% in the cyclophosphamide group experiencing a relapse before maintenance therapy was discontinued. The authors con-

Table 3. Studies on Remission Maintenance in Patients With Generalized Organ-Threatening Disease

Treatment	Azathioprine				Mycophenolate Mofetil			Leflunomide	
	Jayne et al, ⁹ 2003	Mahr et al, ³³ 2005	Sanders et al, ³⁴ 2005	Slot et al, ³⁵ 2004	Nowack et al, ³⁶ 1999	Langford et al, ³⁷ 2004	Koukoulaki and Jayne, ³⁸ 2006	Metzler et al, ³⁹ 2004	Metzler et al, ⁴⁰ 2005
Type of study	Randomized controlled trial	Randomized controlled trial	Retrospective series	Retrospective series	Prospective uncontrolled	Prospective uncontrolled	Retrospective series	Prospective uncontrolled	Randomized controlled trial
No. of patients	71 Azathioprine; 73 Cyclophosphamide	55 Azathioprine; 59 Methotrexate	76 Azathioprine	44 Azathioprine	11	14	29	20	26 Leflunomide; 28 Methotrexate
Time to initiate treatment	After at least 3 mo of remission taking cyclophosphamide	After at least 3 mo of remission taking cyclophosphamide	After 3 mo of remission taking cyclophosphamide	After 3 mo of full remission taking cyclophosphamide	When remission was achieved with cyclophosphamide (mean 14 wk)	When remission was achieved with cyclophosphamide (mean 3 mo)	NS	NS	NS
Initial dose	Azathioprine, 2 mg/kg per d; Cyclophosphamide, 1.5 mg/kg per d	Azathioprine, 2 mg/kg per d; Methotrexate, 0.3 mg/kg per wk	Azathioprine, 1.5-2 mg/kg per d; Cyclophosphamide, 2 mg/kg per d	Azathioprine, 2 mg/kg per d; Cyclophosphamide, 2 mg/kg per d	2 g/d	2 g/d	1 g/d	20 mg/d	Leflunomide, 30 mg/d; Methotrexate, 20 mg/wk
Time of treatment, mean, mo	≤12	12	18	21	14	NS	NS	NS	NS
Follow-up, mean	18 mo	36.8 mo	5 y	5.3 y	14 mo	18 mo from remission	36 mo	1.75 y	NS
Definition of relapse	Major: recurrence or first appearance of at least 1 BVAS item indicative of vital organ threatening; Minor: recurrence or first appearance of at least 3 other BVAS items	NS	NS	Signs of activity + biopsy-proven vasculitis or lung nodules after exclusion of other disorders	BVAS>0	Clinical or histological evidence of disease activity	Clinical features of disease activity	Major: life- or organ-threatening activity requiring reinstitution of cyclophosphamide; Minor: BVAS increase without life- or organ-threatening manifestations	NS
Relapses, %	15.5 Azathioprine; 13.7 Cyclophosphamide	At 18 mo, 13 Azathioprine; 10 Methotrexate At 36 mo, 41 Azathioprine; 37 Methotrexate	At 18 mo, 13.3 Azathioprine; 12 Cyclophosphamide At 5 y, 62.3 Azathioprine; 41 Cyclophosphamide	At 2 y, 24 Azathioprine; 24 Cyclophosphamide At 4 y, 49 Azathioprine; 35 Cyclophosphamide	9 At 14 mo	43 At 18 mo after remission	48	45	23 Leflunomide; 46 Methotrexate

Abbreviations: BVAS, Birmingham Vasculitis Activity Score; NS, not specified.

cluded that although maintenance of immunosuppression beyond 12 months was advisable, continued treatment with methotrexate or cyclophosphamide does not guarantee the absence of relapses. The WGET trial²⁷ revealed no differences between etanercept and placebo groups in rates of sustained remission in non-organ-threatening disease.

Recommendation. To induce remission, methotrexate plus corticosteroids can be used instead of cyclophosphamide in patients with generalized, non-organ-threatening disease. However, when methotrexate is used as maintenance therapy, the likelihood of relapses is high so we recommend rigorous monitoring for early detection. Currently, there is no evidence for the cessation of methotrexate maintenance treatment at 12 months.

Generalized Organ-Threatening Disease (Generalized Disease)

The EUVAS group¹⁷ defined *generalized disease* as patients with Wegener granulomatosis or microscopic polyangiitis with constitutional symptoms, threatened organ function, and serum creatinine levels lower than 5.7 mg/dL. Others have labeled this subgroup as having *life or organ-threatening disease*. To aid joint analysis of different studies, we have defined *generalized organ-threatening disease* as renal insufficiency, serum creatinine levels lower than 5.7 mg/dL, threat to other organs including vital organs, or both.

Remission Induction. Daily oral cyclophosphamide plus corticosteroids substantially advanced the treatment of generalized Wegener granulomatosis⁷ and remains the gold standard therapy. Studies have found remission rates between 70% and 100% and early mortality rates of less than 20%^{9,28,29,37,39,44-49} with increased treatment-related morbidity.^{8,44,50-53} Therefore, research centered on searching for equally effective but safer treatments, including changing the route of administration and dosage of

cyclophosphamide and testing a monthly intravenous regimen.

Ten nonrandomized studies demonstrated similar rates of remission induction with intermittent intravenous cyclophosphamide as those using the daily oral drug.^{16,54-62} The advantage of the intravenous route is the smaller cumulative dosage and, therefore, fewer adverse events. Three randomized trials have compared the effectiveness and security profile of pulsed cyclophosphamide with daily oral administration for remission induction.^{51,63,64} A meta-analysis⁶⁵ that summarized the results from these trials concluded that pulsed cyclophosphamide is as effective as daily oral cyclophosphamide with much less severe toxic effects, yet possibly with a higher relapse rate.

To clarify this controversy, the EUVAS group devised a randomized trial comparing the efficacy of oral cyclophosphamide (2 mg/kg per day) with intravenous pulsed cyclophosphamide (15 mg/kg every 2 weeks for the first 3 pulses and every 3 weeks thereafter) with the same corticosteroids regimen in both groups (Randomised Trial of Daily Oral vs Pulse Cyclophosphamide as Therapy for ANCA-Associated Systemic Vasculitis [CYCLOPS]).⁴ The study included 160 patients with generalized AAV with vital organ manifestations. Preliminary results⁶⁶ show that pulsed cyclophosphamide is equally effective as oral cyclophosphamide for remission induction. Unexpectedly, there were no differences in severe adverse events or deaths between groups.

With regard to biological therapies, the addition of etanercept to cyclophosphamide in the WGET²⁸ trial had no beneficial effect on remission induction. Infliximab—a chimeric IgG1 monoclonal antibody—is another TNF- α blocker that has been used as adjuvant therapy in remission induction. In a prospective uncontrolled study of 16 patients, the addition of infliximab shortened the prior-to-remission period by a mean of 6.4

weeks and allowed early tapering of prednisolone, with a 40% reduction in the cumulative dose compared with standard regimens.⁶⁷

Remission Maintenance. Treatment with pulse cyclophosphamide has been found to be less effective in preventing relapses than oral cyclophosphamide,^{51,54,55,57,59,60} although other reports disagree.^{56,58} The discrepancies may be due to differences in doses and, mainly, pulse administration intervals between studies. Two studies that prolonged cyclophosphamide pulses for another 18 months found lower rates of relapses.^{48,62}

Another way to reduce cyclophosphamide morbidity is to switch this drug with less toxic immunosuppressants, such as azathioprine, mycophenolate mofetil, or leflunomide (Table 3). The efficacy of azathioprine in remission maintenance was initially reported in nonrandomized trials with relapse rates between 11% and 46%.^{49,68-72} The first randomized, prospective study of azathioprine in remission maintenance was the CYCAZAREM (Randomized Trial of Cyclophosphamide vs Azathioprine During Remission in ANCA-Positive Systemic Vasculitis) study by Jayne et al.⁹ Seventy-three patients were randomly assigned to continue cyclophosphamide and 71 switched to azathioprine after remission was achieved with cyclophosphamide and corticosteroids. No difference was found in the relapse rate between the 2 groups at 18 months (15.5% vs 13.7%). Similar relapse rates for those taking azathioprine were reported by a French group³³ in a randomized trial comparing azathioprine with methotrexate in remission maintenance, with no differences being detected in relapse rates.

Recent retrospective studies have shown an increase in the relapse rate for patients treated with azathioprine compared with those treated with cyclophosphamide when extending the follow-up.^{34,35,73} At 5 years, relapse-free survival was slightly lower in the azathioprine group (42.3% vs 57.4%).^{34,73} These studies

indicate that relapses occur predominantly after therapy discontinuation and that patients with generalized AAV with a higher cumulative exposure to cyclophosphamide may have a lower rate of relapse. Finally, in patients with positive proteinase 3-ANCA at the time they switched to azathioprine, disease-free survival at 2 and 4 years was shorter than for patients with negative proteinase 3-ANCA.³⁵

In an open-label trial enrolling 11 patients with AAV who had achieved remission under cyclophosphamide and corticosteroids, mycophenolate mofetil (2 g/d) maintained remission for 15 months in all but 1 patient.³⁶ Conversely, Langford et al³⁷ detected relapses in 6 of 14 patients with Wegener granulomatosis. The differences may be attributed to 2 factors: concomitant steroids were withdrawn after a median of 8 months in the former study but were maintained at low doses in the latter and the trial only involved patients with Wegener granulomatosis, which is known to intrinsically reoccur at a higher rate than microscopic polyangiitis.⁹ In a retrospective study,³⁸ 14 of 29 patients taking mycophenolate mofetil experienced a relapse in a mean of 14 months. These limited, controversial findings may be clarified when the results are available from the International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Vasculitis (IMPROVE) trial, an ongoing randomized trial comparing mycophenolate mofetil with azathioprine for maintenance therapy.¹¹

In a phase 2, open-label trial, oral leflunomide (30-40 mg/d) plus low-dose prednisolone was administered as a maintenance agent to 20 patients with Wegener granulomatosis. During a follow-up of 21 months, 1 major flare was recorded. Eight minor relapses were successfully treated by increasing the leflunomide dose.³⁹ These results led to a multicenter randomized trial⁴⁰ comparing 30-mg daily leflunomide with 20-mg weekly methotrexate in 54 patients with AAV. The trial was interrupted after an unexpectedly high number of severe re-

lapses occurred in the methotrexate group (13 vs 4). Four patients treated with leflunomide were withdrawn due to serious adverse effects (hypertension, neuropathy, and leukopenia). The WGET trial found no differences between etanercept and placebo in rates of sustained remission in patients with organ-threatening disease.²⁷

Recommendation. Pulse cyclophosphamide with oral corticosteroids can be used to induce remission in patients with generalized organ-threatening disease. Patients should be started with 1 mg/kg per day of oral prednisone plus 0.6 to 0.7 g/m² (15 mg/kg; maximal dose: 1 g/m²) intravenous pulse cyclophosphamide (every 3 weeks for 6 months). Prednisone should be tapered to 10 mg by 6 months and maintained at this dose until month 15, when it should be tapered to 7.5 mg and maintained for at least 3 more months followed by local practice. Cyclophosphamide doses should be adjusted by age, renal function, and leukocyte count. The combination of azathioprine and daily prednisone effectively maintains remission. Patients who test negative for ANCA may benefit most with this regimen while patients positive for proteinase 3-ANCA should be closely monitored because they have a higher probability of relapse. Two milligrams per kilogram of azathioprine should be started when cyclophosphamide is discontinued. At 6 months it should be reduced to 1.5 mg/kg per day and maintained for at least 6 more months. In our opinion, leflunomide, methotrexate, and mycophenolate mofetil may be useful alternative therapies to maintain remission.

Severe Renal Vasculitis and Immediately Life-Threatening Disease

Because of a worse prognosis, patients with rapidly progressive renal failure with and without diffuse alveolar hemorrhage have traditionally received a greater immunosuppressive load such as daily pulses of methylprednisolone (1 g) and intravenous cyclophosphamide (3-4 mg/kg per day) over brief periods. However, the evidence supporting this practice is scarce.⁷⁴

Despite use of immunosuppressants, only 50% of patients presenting with advanced renal failure maintain independent renal function at 1 year.^{72,75} Retrospective studies have suggested that plasma exchange may be beneficial for patients with severe renal disease and pulmonary hemorrhage.⁷⁶⁻⁸⁰ Plasma exchange is supposedly effective because it removes ANCAs. In a randomized controlled trial that compared 25 patients with necrotizing glomerulonephritis treated with immunosuppressants plus plasma exchange with 23 patients receiving immunosuppressants alone, Pusey et al⁸¹ found that patients receiving plasma exchange who were initially dialysis-dependent had a greater likelihood of recovering renal function. In a recent multicenter trial,⁴ in which 137 patients with severe renal vasculitis (serum creatinine >5.7 mg/dL) were randomly assigned to undergo plasma exchange or receive pulsed methylprednisolone. Two-thirds of these patients were dialysis-dependent on presentation. All patients were treated with the standard remission induction regimen. Preliminary results show that recovery of independent renal function at 3 months was significantly higher in the plasma exchange group (69% vs 49%). Mortality was 25% with no differences between groups. Therefore, plasma exchange is, at present, the best complement to immunosuppressants in advanced renal disease. Nevertheless, the potential of combining plasma exchange and methylprednisolone in these patients and the use of plasma exchange for less severe renal disease and pulmonary hemorrhage remains unclear.

Refractory Disease

Numerous experimental therapies have recently been used for patients not achieving remission with the gold standard treatment or those with contraindications (TABLE 4). However, there is a lack of randomized trials analyzing the best therapy for these patients and the definition of refractory disease varies widely.

Intravenous Immunoglobulin

Intravenous immunoglobulin may be effective by interfering with ANCAs binding to their antigens (due to anti-idiotypic antibodies) and by inhibiting

ANCAs-mediated neutrophil activation. A retrospective study first revealed a beneficial effect of pooled intravenous immunoglobulin in 1993.⁸⁴ In a randomized, placebo-controlled,

double-blind trial published in 2000,⁸² adding a single course of intravenous immunoglobulin (2 g/kg) to immunosuppressants was significantly effective. The primary end point was the number of pa-

Table 4. Treatments for Patients With Refractory Antineutrophil Cytoplasmic Antibodies–Associated Vasculitis

Source	Wegener Granulomatosis/ Microscopic Polyangiitis	Study Type	Definition of Refractory	No of Patients Refractory to Cyclophosphamide	Primary End Point	Length of Treatment	Responders, %	Definition of Remission	Relapse Rate, %	Mean BVAS at Entry
Intravenous Ig										
Jayne et al, ⁸² 2000	24/10	Double-blind, randomized controlled trial	Active vasculitis needing more therapy and at least 2 mo of treatment with prednisone and cyclophosphamide or azathioprine	NS	Reduction in BVAS by >50% after 3 mo	1 Course of 5 d	83 Intravenous Ig; 35 Placebo ^a	NS	31 Intravenous Ig; 27 Placebo	6.1 Intravenous Ig; 5.4 Placebo
Richter et al, ⁸³ 1995	14/1 ^b	Prospective uncontrolled	Poor responders or intolerant to conventional therapy	7	Clinical and/or radiological improvement after 4 wk	1 Course, 10 patients; 2 Courses, 2 patients; 3 Courses, 3 patients	0 Complete remission; 40 Partial remission	Complete remission: absence of any clinical and/or radiological features of active vasculitis; Partial remission: any improvement	NS	NS
Jayne et al, ⁸⁴ 1993	14/11	Retrospective series	Resistant to conventional therapy	16	Remission rate	1 course of 5 d	50 Complete remission at 8 wk; 50 Partial remission at 8 wk	Authors' "clinical score": 2 = Active 1 = Partial remission 0 = Complete remission	24	NS
Mycophenolate Mofetil										
Stassen et al, ⁸⁵ 2007	29/3	Prospective uncontrolled	Cyclophosphamide contraindication	0	Remission rate	19 mo (1.9-88 mo)	78 Complete remission at 5 mo; 19 Partial remission at 5 mo	Complete remission: BVAS of 0 plus PCR <10 mg/L; Partial remission: "clinically relevant" improvement of BVAS	59	14
15-Deoxyspergualin										
Birck et al, ⁸⁶ 2003	19/1	Prospective uncontrolled	Intractable course, severe adverse effects, frequent relapses, constant low-grade disease under immunosuppressants, or denied to be treated with cytostatics	9	Remission rate after 6 cycles of 15-deoxyspergualin	NS	30 Complete remission; 40 Partial remission	Complete remission: absolute absence of clinical signs of disease activity; Partial remission: absence of acute or newer clinical activity	25 ^c	5.8
Antithymocyte Globulin										
Schmitt et al, ⁸⁷ 2004	15/0	Prospective uncontrolled	Unresponsive to at least 6 wk of standard treatment; Intolerant of standard treatment; Low-grade disease after reduction or omission of immunosuppressants	7	Induction of partial or complete remission for at least 1 mo	2.2 Infusions (1-5) during a 10-d regimen	27 Complete remission; 60 Partial remission	Complete remission: no abnormal clinical and radiological vasculitic findings; Partial remission: partial regression of activity	54	NS

(continued)

Table 4. Treatments for Patients With Refractory Antineutrophil Cytoplasmic Antibodies–Associated Vasculitis (cont)

Source	Wegener Granulomatosis/ Microscopic Polyangiitis	Study Type	Definition of Refractory	No of Patients Refractory to Cyclophosphamide	Primary End Point	Length of Treatment	Responders, %	Definition of Remission	Relapse Rate, %	Mean BVAS at Entry
Infliximab										
Booth et al, ⁶⁷ 2004	12/4	Prospective uncontrolled	Refractoriness to prednisone plus either cyclophosphamide, azathioprine, or methotrexate for at least 3 mo	0	Remission rate	Infusions at 0, 2, 6, and 10 wk	88	Complete remission: BVAS ≤1	20	BVAS >4
Rituximab										
Keogh et al, ⁸⁸ 2005	10/1	Retrospective series	Disease noncontrolled upon maximally tolerated cyclophosphamide dose (with glucocorticoids); Contraindication to cyclophosphamide (drug induced cystitis or cytopenia)	8	Remission rate	Induction with 4 weekly doses ^d	91 Complete remission at 6 mo	BVAS or Wegener granulomatosis of 0	18	6.2
Keogh et al, ⁸⁹ 2006	10/0	Prospective uncontrolled	Disease noncontrolled upon maximally tolerated cyclophosphamide dose (with glucocorticoids); Contraindication to cyclophosphamide (drug induced cystitis, cytopenia, or malignancies within the last 5 y)	3	Remission rate	Induction with 4 weekly doses ^e	100 Complete remission at 3 mo	BVAS or Wegener granulomatosis of 0	10	6

Abbreviations: ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; Ig, immunoglobulin; NS, not specified; PCR, polymerase chain reaction.

^aSignificant positive effect, $P = .015$.

^bMyeloperoxidase-ANCA vasculitis with eye involvement.

^cOne out of 4 responder patients who were maintained with deoxyspergualin relapsed. The rest were maintained with other immunosuppressants (20% relapse rate).

^dAdditional courses were administered in case of relapse, elevation of ANCA, or B-cells titers (4 patients = 2 courses; 2 patients = 3 courses in the follow-up).

^eAdditional courses of rituximab were administered in case of relapse or elevation of ANCA titers (3 patients = 1 course; 7 patients = 2 courses in the follow-up).

tients with decreased Birmingham Vasculitis Activity Score (BVAS) of at least 50% at 3 months. However, there were no significant differences in either the score beyond 3 months or the exposure to immunosuppressants following intravenous immunoglobulin.

Mycophenolate Mofetil

Stassen et al⁸⁵ recently reported the results of a study in which 32 patients were initially treated with mycophenolate mofetil (2 g/d) plus prednisolone (1 mg/kg per day). After 2.2 months, 78% of patients achieved complete remission. Maintenance therapy with mycophenolate mofetil yielded a 59% rate of relapse within a median of 12 months. Sixteen infectious episodes were seen in 12 patients while taking mycophenolate mofetil. Thus, mycophenolate mofetil seems to be able to suppress activity in acute disease.

15-Deoxyspergualin

In an open-label trial, Birck et al⁸⁶ found that 6 cycles of subcutaneous or intravenous 15-deoxyspergualin (0.5 mg/kg per day) for 6 months led to clinical improvement in 70% of cases. The favorable adverse effect profile with no renal and liver toxicity and with reversible bone marrow suppression suggests that 15-deoxyspergualin is a promising therapy.

Antithymocyte Globulin

Because activated CD4 T cells producing T-helper type 1 cytokines seem to play a crucial role in AAV,³² there exists a rationale for the use of T-lymphocyte blocking therapies (Figure 1). The infusion of antithymocyte globulin causes rapid, deep depletion of T lymphocytes. In a prospective, uncontrolled trial,⁸⁷ a 10-day

regimen of antithymocyte globulin–induced remission in 13 of 15 patients with Wegener granulomatosis. Remission was seen in 6 of 7 patients with persistent activity despite cyclophosphamide, and in 7 of 8 patients in whom cyclophosphamide was contraindicated. Due to the potential adverse effects of antithymocyte globulin, including pulmonary edema, the authors recommended avoiding the drug in cases of infection and balancing its risk against possible benefits in cases of pulmonary hemorrhage.

Rituximab

Rituximab is a chimeric monoclonal anti-CD20 IgG1 antibody that induces apoptosis of B lineage cells, with the exception of plasma cells and pre-B cells. Infusion of rituximab causes a 6-month depletion of circulating B cells.

Besides non-Hodgkin B-cell lymphoma, rituximab is effective against several autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosus.¹² In AAV, the depletion of B cells, the immediate precursors of plasma cells, might halt the replacement of true ANCA-producing cells (ie, CD20 negative plasma cells; Figure 1) leading to the disappearance of pathogenic antibodies and the resolution of vasculitic lesions. This hypothesis is supported by the assumption that ANCA-producing plasma cells have a short lifespan.⁹⁰

The best evidence for the treatment of refractory AAV with rituximab emerges from a small retrospective series⁸⁸ and a prospective study.⁸⁹ The maximum tolerated dose of cyclophosphamide failed to control disease activity in 11 of 21 individuals. Immunosuppressive agents were removed at initiation of rituximab (4 weekly doses of 375 mg/m²); the treatment protocol included initial high-dose prednisone (1 mg/kg per day) and, in some patients, a 3-day cycle of methylprednisolone (1 g/d).^{88,89} Prednisone was withdrawn at 6 months in most patients. Complete remission was seen in 95% patients at 3 to 6 months. Even though ANCA concentrations decreased in all patients, the ANCA determination remained positive in 7 patients. No relapses were detected while circulating B cells were absent. In the prospective trial,⁸⁹ patients displaying an increase in ANCA levels during remission, were treated preemptively with rituximab alone, with only 1 patient relapsing during a follow-up of 1 year.

Infliximab

Booth et al⁶⁷ reported that the addition of infliximab led to an 88% remission rate in 16 AAV patients with persistent activity in spite of immunosuppressive therapy. Infliximab eased glucocorticoid tapering and responders were maintained with periodic infusions plus the initial regimen, which included azathioprine, mycophenolate mofetil, methotrexate, and cotrimoxazole. There were 4 infections, some serious.

Churg-Strauss Syndrome

Most studies of Churg-Strauss syndrome treatment have been performed by the French Vasculitis Study Group,⁹¹⁻⁹⁵ which proposed the 5-factors score as a predictor of death in Churg-Strauss syndrome⁹⁶: (1) renal insufficiency (creatinine level >1.58 mg/dL); (2) proteinuria higher than 1 g/d; (3) gastrointestinal bleeding, perforation, infarction, or pancreatitis; (4) central nervous system involvement; and (5) cardiomyopathy. The presence of each factor is given 1 point. Three classes of scores are defined as 0 when no factor is noted; 1 when 1 factor is present, and 2 when 2 or more factors are present. The score is associated with a higher risk of mortality when it is 1 or higher.

This score is useful in deciding the first-line of treatment. In one study, early deaths of patients with a 5-factors score of 2 were more frequent when steroids were prescribed alone.⁹⁷ A meta-analysis of the French Vasculitis Study Group trials showed improved outcomes after early administration of oral cyclophosphamide in patients with severe manifestations (score, ≥1) at onset.⁹⁵ This group also demonstrated that the addition of plasma exchange to the combined treatment of corticosteroids and pulse cyclophosphamide did not enhance the 5-year cumulative survival rates in patients with severe (score, ≥1) Churg-Strauss syndrome.⁹³ More than 80% of survivors in long-term remission had persistent asthma requiring permanent low doses of oral or inhaled corticosteroids.⁹⁸ The duration of the immunosuppressive treatment is also controversial in Churg-Strauss syndrome. Preliminary prospective data suggest that patients receiving 6 pulses of cyclophosphamide had more relapses than those receiving 12 pulses (94% vs 41%).⁹⁹

Recommendation. Treatment can be started with high doses of corticosteroids (1 mg/kg per day), tapering them when the patient improves. In patients with a 5-factors score equal to or greater than 1 or when corticosteroids fail, cyclophosphamide should be in-

troduced to induce remission, which may be maintained with another less toxic drug.

Controversies and Uncertainties

How long should immunosuppression be maintained? Unfortunately, reported studies cannot answer this question. Although indirect data from randomized trials indicate that maintenance treatment of at least 12 to 18 months would be necessary for generalized AAV,⁹ recent data indicate that relapses occur predominantly after therapy discontinuation.³⁵ We believe that it is reasonable to consider discontinuing methotrexate or azathioprine in the total absence of clinical signs of vasculitis activity and especially in the cases of patients who test negative for ANCA and patients without previous relapses. However, rigorous monitoring is mandatory for early detection of relapses. This question may be answered by the Randomized Trial of Prolonged Remission-Maintenance Therapy in Systemic Vasculitis (REMAIN), an ongoing trial in which 2 years vs 4 years of azathioprine and prednisolone are being compared in patients with renal vasculitis.¹⁷

Biologic Therapy for AAV

The dramatic results for rituximab should be interpreted with caution.^{88,89} It is difficult to determine the true efficacy of rituximab in AAV in reported studies due to the simultaneous administration of high-dose glucocorticoids, which may contribute to ANCA negativization and the remission rates observed.⁹⁰ Furthermore, the intrinsic ability of rituximab to reduce autoantibody levels remains unproven because ANCA may persist after infusion despite B cell depletion.³² This may be because ANCA can be continuously produced by long-lived plasma cells. It is possible that rituximab acts through immunological mechanisms other than the suppression of ANCA production (eg, by inhibiting B cell-dependent T cell functions). This uncertainty may be clarified by an

ongoing randomized, placebo-controlled trial exploring the potential role of rituximab plus corticosteroids (vs cyclophosphamide plus corticosteroids for induction and azathioprine plus corticosteroids for remission) in both induction and maintenance phases.

The apparently positive data on infliximab, added to laboratory research suggesting a fundamental role for TNF- α in AAV, justify the design of a randomized trial to determine whether this molecule, unlike etanercept, could become a therapeutic mainstay in AAV. Due to its molecular structure, infliximab-induced soluble TNF- α blockade is more complete and sustained. In addition, infliximab can bind membrane-bound TNF- α and activate apoptosis of T cells. This binding to surface TNF- α also induces cell lysis via complement fixation. Infliximab has also been found to down regulate T-cell cytokine response (TNF- α and interferon γ) after specific and nonspecific in vitro stimuli, whereas etanercept up regulated this response.¹⁰⁰⁻¹⁰² These differences may explain why infliximab but not etanercept has succeeded in treating Crohn disease, otherwise a granulomatous disorder.

FUTURE DIRECTIONS AND CONCLUSIONS

The agents that have accumulated the highest evidence are not as effective and safe as would be desirable. Therefore, research should focus on clarifying and consolidating the evidence for new immunosuppressants and those biological agents that have been initially successful (rituximab and infliximab). These agents may reduce the rate of relapses and increase safety, challenging the status quo of immunosuppressive therapy in AAV.

High-quality, comparable evidence requires studies following homogeneous guidelines. Definitions of disease activity (eg, remission, relapse), disease states (eg, localized, early systemic), and treatment protocols (eg, same regimen of corticosteroids tapering) should be systematic and consistent. The European

League Against Rheumatism has recently issued evidence-based and expert-opinion-based recommendations for AAV trials.¹⁰³

A new set of biological molecules is under consideration. A series of sophisticated agents directed against key pathogenic points, with proven efficacy in some autoimmune conditions, may well deserve clinical investigation for AAV. A reasonable strategy to suppress the autoimmune cellular response might be the blockage of co-stimulating molecules that intervene in the antigen presenting cell-dependent T cell activation (eg, by using abatacept¹⁰⁴; Figure 1) which is thought to be the initial step in Wegener granulomatosis granuloma formation. At the vasculitic pole of the spectrum, monoclonal antibodies and fusion proteins aimed at inhibiting ANCA, suppressing neutrophil priming and endothelial activation, and interfering in the neutrophil-endothelium adhesion cascade or neutrophil degranulation might also prove fundamental in healing vasculitic damage (Figure 2).

The success of novel agents requires trials designed according to pathogenic knowledge. Patients might not only benefit from therapies tailored to disease severity but also may be treated according to clinical manifestations and biological markers reflecting the susceptible-to-block pathogenic pathway. As long as safety concerns are overcome, this strategy might even involve the combined use of agents in overlapping situations (eg, simultaneous presence of orbital granulomata and necrotizing alveolar capillaritis).

Author Contributions: Dr Bosch had full access to all the data in the study and takes responsibility for the integrity and the accuracy of the data analysis.

Study concept and design: Bosch, Guilabert, Espinosa, Mirapeix.

Acquisition of data: Bosch, Guilabert, Espinosa, Mirapeix.

Analysis and interpretation of data: Bosch, Guilabert, Espinosa, Mirapeix.

Drafting of the manuscript: Bosch, Guilabert, Espinosa, Mirapeix.

Critical revision of the manuscript for important intellectual content: Bosch, Guilabert, Espinosa, Mirapeix.

Statistical analysis: Bosch.

Administrative, technical, or material support: Bosch, Guilabert, Espinosa, Mirapeix.

Study supervision: Bosch, Guilabert, Espinosa, Mirapeix.

Financial Disclosures: None reported.

Additional Contribution: We thank Mónica Pérez-Poquet, MD, for her invaluable collaboration in the design of the figures of the manuscript. She was not compensated for her contribution.

REFERENCES

1. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. *Lancet*. 2006;368(9533):404-418.
2. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. *Am J Med*. 2004;117(1):39-50.
3. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis: estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. *Arthritis Rheum*. 1996;39(1):87-92.
4. de Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? take home messages from the 12th workshop on ANCA and systemic vasculitides. *Clin Nephrol*. 2005;64(6):480-484.
5. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). *Br Med J*. 1958;2(5091):265-270.
6. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. *Ann Intern Med*. 1967;67(2):393-398.
7. Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. *Medicine (Baltimore)*. 1973;52(6):535-561.
8. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med*. 1992;116(6):488-498.
9. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med*. 2003;349(1):36-44.
10. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*. 2005;52(8):2461-2469.
11. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. *Curr Opin Rheumatol*. 2006;18(1):25-32.
12. Flossmann O, Jones RB, Jayne DR, Luqmani RA. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? *Ann Rheum Dis*. 2006;65(7):841-844.
13. Goek ON, Stone JH. Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. *Curr Opin Rheumatol*. 2005;17(3):257-264.
14. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. *Arthritis Rheum*. 1994;37(2):187-192.
15. Bosch X. Microscopic polyangiitis (microscopic polyarteritis) with late emergence of generalised Wegener's granulomatosis. *Ann Rheum Dis*. 1999;58(10):644-647.
16. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. *Arthritis Rheum*. 1994;37(6):919-924.
17. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. *Mayo Clin Proc*. 1997;72(8):737-747.
18. DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment

- with antimicrobial agents. *Mayo Clin Proc.* 1985; 60(1):27-32.
19. DeRemee RA. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? *Arthritis Rheum.* 1988;31(8):1068-1074.
 20. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. *QJM.* 1996;89(1):15-23.
 21. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG; Dutch Co-Trimoxazole Wegener Study Group. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. *N Engl J Med.* 1996;335(1):16-20.
 22. Oxford Centre for Evidence-Based Medicine. Levels of evidence and grades of recommendation. http://www.cebm.net/levels_of_evidence.asp. Accessed May 21, 2007.
 23. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. *Arthritis Rheum.* 1992; 35(11):1322-1329.
 24. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. *Arthritis Rheum.* 1995; 38(5):608-613.
 25. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. *J Rheumatol.* 1999;26(5):1134-1139.
 26. de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low dose methotrexate. *J Rheumatol.* 1998;25(3):492-495.
 27. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). *Control Clin Trials.* 2002;23(4):450-468.
 28. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. *N Engl J Med.* 2005;352(4):351-361.
 29. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. *Am J Med.* 2003;114(6):463-469.
 30. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. *Arthritis Rheum.* 2002;47(3):326-332.
 31. Jayne D. What place for the new biologics in the treatment of necrotizing vasculitides. *Clin Exp Rheumatol.* 2006;24(2)(suppl 41):S1-S5.
 32. Sarraf P, Kay J, Friday RP, Reginato AM. Wegener's granulomatosis: is biologic therapy useful? *Curr Rheumatol Rep.* 2006;8(4):303-311.
 33. Mahr A, Pagnoux C, Cohen C, et al. Treatment of ANCA-associated vasculitides: corticosteroids and pulse cyclophosphamide followed by maintenance therapy with methotrexate or azathioprine: a prospective multicenter randomized trial (WEGENT). *Kidney Blood Press Res.* 2005;28:194.
 34. Sanders JSF, Stassen PM, Kallenberg CGM, Stegeman CA. Azathioprine as compared to cyclophosphamide maintenance therapy for ANCA-associated vasculitis is associated with increased long-term relapse risk. *Kidney Blood Press Res.* 2005;28:195.
 35. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. *Arthritis Rheum.* 2004;51(2):269-273.
 36. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. *J Am Soc Nephrol.* 1999;10(9):1965-1971.
 37. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. *Arthritis Rheum.* 2004;51(2):278-283.
 38. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. *Nephron Clin Pract.* 2006;102(3-4): c100-c107.
 39. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. *Rheumatology (Oxford).* 2004;43(3):315-320.
 40. Metzler C, Wagner-Bastmeyer R, Gross WL, Reinhold-Keller E. Leflunomide versus methotrexate for maintenance of remission in Wegener's granulomatosis: Unexpected high relapse rate under oral methotrexate. *Ann Rheum Dis.* 2005;64(1)(suppl 3): 85.
 41. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. *Arthritis Rheum.* 1999;42(12):2666-2673.
 42. de Groot K, Reinhold-Keller E, Tatsis E, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. *Arthritis Rheum.* 1996;39(12):2052-2061.
 43. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. *Arthritis Rheum.* 2000;43(8):1836-1840.
 44. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. *Arthritis Rheum.* 2000;43(5):1021-1032.
 45. Hoffman GS. "Wegener's granulomatosis": the path traveled since 1931. *Medicine (Baltimore).* 1994; 73(6):325-329.
 46. Brandwein S, Esdaile J, Danoff D, Tannenbaum H. Wegener's granulomatosis: clinical features and outcome in 13 patients. *Arch Intern Med.* 1983;143(3): 476-479.
 47. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. *Arthritis Rheum.* 2000;43(9):2025-2033.
 48. Dhaygude A, Griffith M, Cairns T, McLean A, Palmer A, Taube D. Prolonged treatment with low-dose intravenous pulse cyclophosphamide may reduce rate of relapse in ANCA-associated vasculitis. *Nephron Clin Pract.* 2004;97(4):c154-c159.
 49. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. *Ann Intern Med.* 1983;98(1):76-85.
 50. Lynch JP III, White E, Tazelaar H, Langford CA. Wegener's granulomatosis: evolving concepts in treatment. *Semin Respir Crit Care Med.* 2004;25(5): 491-521.
 51. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. *Arthritis Rheum.* 1997; 40(12):2187-2198.
 52. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. *Rheumatology (Oxford).* 2001;40(5):492-498.
 53. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. *Ann Intern Med.* 1996;124(5):477-484.
 54. Koldingsnes W, Gran JT, Omdal R, Husby G. Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. *Br J Rheumatol.* 1998;37(6):659-664.
 55. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. *Am J Med.* 1990;89(4):403-410.
 56. Falk RJ, Hogan S, Carey TS, Jennette JC; The Glomerular Disease Collaborative Network. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. *Ann Intern Med.* 1990;113(9):656-663.
 57. Boki KA, Dafni U, Karpouzas GA, Papasteriades C, Drosos AA, Moutsopoulos HM. Necrotizing vasculitis in Greece: clinical, immunological, and immunogenetic aspects: a study of 66 patients. *Br J Rheumatol.* 1997;36(10):1059-1066.
 58. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. *Nephrol Dial Transplant.* 1991;6(8): 531-535.
 59. Lê Thi Huong D, Papo T, Piette JC, et al. Monthly intravenous pulse cyclophosphamide therapy in Wegener's granulomatosis. *Clin Exp Rheumatol.* 1996;14(1):9-16.
 60. Drosos AA, Sakkas LI, Goussia A, Siamopoulos KC, Moutsopoulos HM. Pulse cyclophosphamide therapy in Wegener's granulomatosis: a pilot study. *J Intern Med.* 1992;232(3):279-282.
 61. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. *Ann Rheum Dis.* 1997;56(8):481-487.
 62. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. *Arthritis Rheum.* 2003;49(1):93-100.
 63. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. *QJM.* 1997;90(6):401-409.
 64. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. *Arthritis Rheum.* 1998;41(10):1835-1844.
 65. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. *Nephrol Dial Transplant.* 2001;16(10):2018-2027.
 66. De Groot K, Jayne CRW, Tesar V. Savage COS for EUVAS. Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis. *Kidney Blood Press Res.* 2005;28:195.
 67. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. *J Am Soc Nephrol.* 2004;15(3):717-721.
 68. Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology, and prognosis. *Q J Med.* 1985;56(220):467-483.
 69. Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. *Q J Med.* 1993; 86(12):779-789.
 70. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. *QJM.* 1995;88(2):127-133.

71. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and antineutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. *Am J Kidney Dis.* 1995;25(3):380-389.
72. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. *J Am Soc Nephrol.* 1998;9(5):842-852.
73. Sanders JS, Slot MC, Stegeman CA. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med.* 2003;349(21):2072-2073.
74. White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. *Drugs.* 2006;66(9):1209-1228.
75. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. *Am J Kidney Dis.* 2003;41(4):776-784.
76. Frascà GM, Zoumparidis NG, Borgnino LC, Neri L, Vangelista A, Bonomini V. Plasma exchange treatment in rapidly progressive glomerulonephritis associated with anti-neutrophil cytoplasmic autoantibodies. *Int J Artif Organs.* 1992;15(3):181-184.
77. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Jorstad S. Clinical outcome of patients with Wegener's granulomatosis treated with plasma exchange. *Blood Purif.* 2002;20(2):167-173.
78. Klemmer PJ, Chalmerskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. *Am J Kidney Dis.* 2003;42(6):1149-1153.
79. Frascà GM, Soverini ML, Falaschini A, Tampieri E, Vangelista A, Stefoni S. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. *Ther Apher Dial.* 2003;7(6):540-546.
80. Kokolina E, Alexopoulos E, Dimitriadis C, et al. Immunosuppressive therapy and clinical evolution in forty-nine patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis. *Ann N Y Acad Sci.* 2005;1051:597-605.
81. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. *Kidney Int.* 1991;40(4):757-763.
82. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. *QJM.* 2000;93(7):433-439.
83. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. *Clin Exp Immunol.* 1995;101(1):2-7.
84. Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. *Adv Exp Med Biol.* 1993;336:469-472.
85. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active ANCA-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. *Ann Rheum Dis.* 2007;66(6):798-802.
86. Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. *J Am Soc Nephrol.* 2003;14(2):440-447.
87. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. *Kidney Int.* 2004;65(4):1440-1448.
88. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum.* 2005;52(1):262-268.
89. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. *Am J Respir Crit Care Med.* 2006;173(2):180-187.
90. Sneller MC. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? *Arthritis Rheum.* 2005;52(1):1-5.
91. Guillevin L, Jarrousse B, Lok C, et al; The Cooperative Study Group for Polyarteritis Nodosa. Long-term followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange: a prospective randomized trial of 71 patients. *J Rheumatol.* 1991;18(4):567-574.
92. Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome: a prospective, randomized trial in 78 patients. *Arthritis Rheum.* 1992;35(2):208-215.
93. Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a prospective, randomized trial in sixty-two patients. *Arthritis Rheum.* 1995;38(11):1638-1645.
94. Gayraud M, Guillevin L, Cohen P, et al; French Cooperative Study Group for Vasculitides. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. *Br J Rheumatol.* 1997;36(12):1290-1297.
95. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. *Arthritis Rheum.* 2001;44(3):666-675.
96. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. *Medicine (Baltimore).* 1996;75(1):17-28.
97. Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. *Medicine (Baltimore).* 2005;84(5):323-330.
98. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. *Medicine (Baltimore).* 1999;78(1):26-37.
99. Pagnoux C, Cohen P, Mahr A, et al. Treatment of Churg-Strauss syndrome with poor prognostic factors. A prospective, randomized, multicenter trial comparing corticosteroids and 6 vs 12 cyclophosphamide pulses. *Arthritis Rheum.* 2003;49:S661.
100. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor (alpha) blockade in Wegener's granulomatosis. *Ann Rheum Dis.* 2005;64(suppl 4):iv31-iv36.
101. Rosenstiel P, Agnholt J, Kelsen J, et al. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease. *Gut.* 2005;54(2):314-315.
102. Sieper J, Van Den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes. *Semin Arthritis Rheum.* 2005;34(5)(suppl 1):23-27.
103. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on ANCA-associated vasculitis. *Ann Rheum Dis.* 2007;66(5):605-617.
104. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med.* 2005;353(11):1114-1123.